

**Sexually
Transmitted
Disease
Surveillance
2020:
Enhanced Gonococcal Isolate
Surveillance Project
Site-Specific Profiles**

**Division of STD Prevention
August 2022**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION
DIVISION OF STD PREVENTION
ATLANTA, GEORGIA 30329-4027**

Acknowledgments

2

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Sancta St. Cyr, Kristen Kreisel, and Hillard Weinstock, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Cau Pham, Brian Raphael, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2020: Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles*. Atlanta: U.S. Department of Health and Human Services; 2022.

Web Site

The online version of this report is available at <https://www.cdc.gov/std/gisp/default.htm>.


2020 Enhanced Gonococcal Isolate Surveillance Project Clinical Sites and Years Participated

Chicago, Illinois (2018–2020)	Minneapolis, Minnesota (2018–2019)	Phoenix, Arizona (2020)
Columbus, Ohio (2018–2020)	New Orleans, Louisiana (2018–2020)	Pontiac, Michigan (2018–2019)
Kalamazoo, Michigan (2018)	Orange County, California (2018–2020)	Portland, Oregon (2018)
Las Vegas, Nevada (2018–2020)	Philadelphia, Pennsylvania (2018–2020)	San Diego, California (2018–2020)
Miami, Florida (2018)		

2020 Enhanced Gonococcal Isolate Surveillance Project Regional Laboratories

Maryland Department of Health and Mental Hygiene <i>Baltimore, Maryland</i>
Tennessee Department of Health <i>Nashville, Tennessee</i>
Texas Department of State Health Services <i>Austin, Texas</i>
Washington State Department of Health <i>Seattle, Washington</i>


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	2 (2.0)	70 (71.4)	0 (0)	9 (9.2)	17 (17.3)	0 (0)	0 (0)	98
Genital	2019	0 (0)	0 (0)	87 (68.5)	1 (0.8)	12 (9.4)	23 (18.1)	0 (0)	4 (3.1)	127
Genital	2020	0 (0)	1 (4.3)	16 (69.6)	0 (0)	1 (4.3)	4 (17.4)	0 (0)	1 (4.3)	23
Pharyngeal	2018	0 (0)	1 (12.5)	4 (50.0)	0 (0)	3 (37.5)	0 (0)	0 (0)	0 (0)	8
Pharyngeal	2019	0 (0)	0 (0)	2 (33.3)	0 (0)	2 (33.3)	2 (33.3)	0 (0)	0 (0)	6
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	1 (7.7)	5 (38.5)	0 (0)	3 (23.1)	4 (30.8)	0 (0)	0 (0)	13
Rectal	2019	0 (0)	1 (12.5)	1 (12.5)	0 (0)	3 (37.5)	3 (37.5)	0 (0)	0 (0)	8
Rectal	2020	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	2

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	4 (50.0)	0 (0)	0 (0)	3 (37.5)	0 (0)	1 (12.5)	8
Genital	2019	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Pharyngeal	2018	0 (0)	0 (0)	4 (57.1)	0 (0)	0 (0)	3 (42.9)	0 (0)	0 (0)	7
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	2
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100.0)	0 (0)	0 (0)	3
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Rectal	2019	0 (0)	0 (0)	2 (66.7)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	3
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	28	69	8	105
Genital	2019	32	95	1	128
Genital	2020	14	9	1	24
Pharyngeal	2018	7	1	7	15
Pharyngeal	2019	6	0	2	8
Pharyngeal	2020	0	0	3	3
Rectal	2018	13	0	1	14
Rectal	2019	8	0	3	11
Rectal	2020	2	0	0	2

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	69 (65.1)	24 (22.6)	12 (11.3)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	106
Genital	2019	94 (73.4)	30 (23.4)	3 (2.3)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	128
Genital	2020	17 (70.8)	6 (25.0)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24
Pharyngeal	2018	6 (40.0)	3 (20.0)	5 (33.3)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2019	3 (37.5)	3 (37.5)	2 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2020	1 (33.3)	2 (66.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2018	6 (42.9)	6 (42.9)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2019	6 (54.5)	3 (27.3)	2 (18.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2020	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	21 (19.8)	71 (67.0)	4 (3.8)	7 (6.6)	2 (1.9)	0 (0.0)	0 (0.0)	1 (0.9)	106
Genital	2019	27 (21.1)	68 (53.1)	9 (7.0)	18 (14.1)	6 (4.7)	0 (0.0)	0 (0.0)	0 (0.0)	128
Genital	2020	6 (25.0)	9 (37.5)	1 (4.2)	6 (25.0)	2 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	24
Pharyngeal	2018	4 (26.7)	11 (73.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2019	1 (12.5)	4 (50.0)	1 (12.5)	1 (12.5)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2020	0 (0.0)	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2018	1 (7.1)	11 (78.6)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2019	0 (0.0)	5 (45.5)	1 (9.1)	4 (36.4)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2020	0 (0.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	81 (76.4)	2 (1.9)	0 (0.0)	6 (5.7)	17 (16.0)	106
Genital	2019	85 (66.4)	0 (0.0)	0 (0.0)	8 (6.3)	35 (27.3)	128
Genital	2020	17 (70.8)	0 (0.0)	0 (0.0)	2 (8.3)	5 (20.8)	24
Pharyngeal	2018	8 (53.3)	0 (0.0)	0 (0.0)	3 (20.0)	4 (26.7)	15
Pharyngeal	2019	5 (62.5)	0 (0.0)	0 (0.0)	2 (25.0)	1 (12.5)	8
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	1 (33.3)	2 (66.7)	3
Rectal	2018	8 (57.1)	0 (0.0)	0 (0.0)	1 (7.1)	5 (35.7)	14
Rectal	2019	7 (63.6)	0 (0.0)	0 (0.0)	0 (0.0)	4 (36.4)	11
Rectal	2020	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	2 (7.1)	1 (1.4)	0 (0.0)	3
Genital	2019	3 (9.4)	3 (3.2)	0 (0.0)	6
Genital	2020	2 (14.3)	0 (0.0)	0 (0.0)	2
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	1 (16.7)	0 (0.0)	0 (0.0)	1
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	1 (12.5)	0 (0.0)	0 (0.0)	1
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Chicago, Illinois, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	9 (32.1)	12 (17.4)	2 (25.0)	23
Genital	2019	13 (40.6)	30 (31.6)	0 (0.0)	43
Genital	2020	6 (42.9)	0 (0.0)	1 (100.0)	7
Pharyngeal	2018	5 (71.4)	0 (0.0)	2 (28.6)	7
Pharyngeal	2019	3 (50.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2020	0 (0.0)	0 (0.0)	3 (100.0)	3
Rectal	2018	6 (46.2)	0 (0.0)	0 (0.0)	6
Rectal	2019	4 (50.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 µg/ml.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	24 (8.0)	60 (20.0)	55 (18.3)	44 (14.7)	34 (11.3)	20 (6.7)	24 (8.0)	17 (5.7)	14 (4.7)	5 (1.7)	3 (1.0)	300
Genital	2019	19 (6.3)	43 (14.3)	67 (22.3)	41 (13.7)	32 (10.7)	23 (7.7)	27 (9.0)	19 (6.3)	15 (5.0)	7 (2.3)	7 (2.3)	300
Genital	2020	6 (5.4)	21 (18.8)	25 (22.3)	14 (12.5)	16 (14.3)	11 (9.8)	7 (6.3)	3 (2.7)	4 (3.6)	4 (3.6)	1 (0.9)	112
Pharyngeal	2018	1 (2.1)	9 (18.8)	14 (29.2)	8 (16.7)	4 (8.3)	6 (12.5)	1 (2.1)	2 (4.2)	1 (2.1)	2 (4.2)	0 (0)	48
Pharyngeal	2019	3 (9.4)	8 (25.0)	8 (25.0)	5 (15.6)	3 (9.4)	2 (6.3)	1 (3.1)	1 (3.1)	0 (0)	0 (0)	1 (3.1)	32
Pharyngeal	2020	3 (17.6)	4 (23.5)	5 (29.4)	1 (5.9)	3 (17.6)	0 (0)	1 (5.9)	0 (0)	0 (0)	0 (0)	0 (0)	17
Rectal	2018	3 (10.3)	8 (27.6)	4 (13.8)	5 (17.2)	1 (3.4)	2 (6.9)	2 (6.9)	2 (6.9)	1 (3.4)	1 (3.4)	0 (0)	29
Rectal	2019	1 (5.3)	6 (31.6)	5 (26.3)	3 (15.8)	0 (0)	2 (10.5)	1 (5.3)	0 (0)	1 (5.3)	0 (0)	0 (0)	19
Rectal	2020	1 (8.3)	6 (50.0)	1 (8.3)	1 (8.3)	1 (8.3)	0 (0)	0 (0)	0 (0)	2 (16.7)	0 (0)	0 (0)	12


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (0.3)	213 (71.0)	0 (0)	68 (22.7)	11 (3.7)	3 (1.0)	4 (1.3)	300
Genital	2019	1 (0.3)	1 (0.3)	219 (73.0)	1 (0.3)	54 (18.0)	11 (3.7)	9 (3.0)	4 (1.3)	300
Genital	2020	0 (0)	0 (0)	88 (78.6)	1 (0.9)	20 (17.9)	2 (1.8)	1 (0.9)	0 (0)	112
Pharyngeal	2018	0 (0)	0 (0)	27 (56.3)	0 (0)	19 (39.6)	2 (4.2)	0 (0)	0 (0)	48
Pharyngeal	2019	0 (0)	0 (0)	20 (62.5)	0 (0)	8 (25.0)	3 (9.4)	0 (0)	1 (3.1)	32
Pharyngeal	2020	0 (0)	0 (0)	12 (70.6)	0 (0)	2 (11.8)	2 (11.8)	1 (5.9)	0 (0)	17
Rectal	2018	0 (0)	0 (0)	8 (27.6)	0 (0)	21 (72.4)	0 (0)	0 (0)	0 (0)	29
Rectal	2019	0 (0)	0 (0)	9 (47.4)	0 (0)	10 (52.6)	0 (0)	0 (0)	0 (0)	19
Rectal	2020	0 (0)	0 (0)	4 (33.3)	0 (0)	8 (66.7)	0 (0)	0 (0)	0 (0)	12

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (1.8)	43 (76.8)	0 (0)	12 (21.4)	0 (0)	0 (0)	0 (0)	56
Genital	2019	0 (0)	2 (3.3)	44 (73.3)	0 (0)	11 (18.3)	2 (3.3)	1 (1.7)	0 (0)	60
Genital	2020	1 (7.7)	0 (0)	9 (69.2)	0 (0)	2 (15.4)	0 (0)	1 (7.7)	0 (0)	13
Pharyngeal	2018	0 (0)	0 (0)	19 (76.0)	0 (0)	5 (20.0)	1 (4.0)	0 (0)	0 (0)	25
Pharyngeal	2019	0 (0)	2 (6.7)	19 (63.3)	0 (0)	8 (26.7)	1 (3.3)	0 (0)	0 (0)	30
Pharyngeal	2020	0 (0)	0 (0)	3 (60.0)	0 (0)	2 (40.0)	0 (0)	0 (0)	0 (0)	5
Rectal	2018	0 (0)	0 (0)	6 (85.7)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	7
Rectal	2019	0 (0)	0 (0)	3 (50.0)	0 (0)	2 (33.3)	1 (16.7)	0 (0)	0 (0)	6
Rectal	2020	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	57	243	56	356
Genital	2019	51	249	60	360
Genital	2020	25	86	13	124
Pharyngeal	2018	26	22	25	73
Pharyngeal	2019	17	15	30	62
Pharyngeal	2020	11	5	5	21
Rectal	2018	29	0	7	36
Rectal	2019	19	0	6	25
Rectal	2020	12	0	2	14

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	233 (65.4)	77 (21.6)	35 (9.8)	10 (2.8)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	356
Genital	2019	260 (72.2)	65 (18.1)	33 (9.2)	2 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	360
Genital	2020	90 (72.0)	30 (24.0)	5 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	125
Pharyngeal	2018	43 (58.9)	17 (23.3)	11 (15.1)	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	73
Pharyngeal	2019	41 (66.1)	13 (21.0)	8 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	62
Pharyngeal	2020	15 (68.2)	5 (22.7)	1 (4.5)	1 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Rectal	2018	23 (63.9)	8 (22.2)	5 (13.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	36
Rectal	2019	20 (80.0)	5 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Rectal	2020	13 (92.9)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	95 (26.7)	164 (46.1)	36 (10.1)	31 (8.7)	26 (7.3)	1 (0.3)	1 (0.3)	2 (0.6)	356
Genital	2019	78 (21.7)	167 (46.4)	32 (8.9)	60 (16.7)	18 (5.0)	3 (0.8)	1 (0.3)	1 (0.3)	360
Genital	2020	15 (12.0)	50 (40.0)	27 (21.6)	12 (9.6)	11 (8.8)	9 (7.2)	1 (0.8)	0 (0.0)	125
Pharyngeal	2018	14 (19.2)	32 (43.8)	11 (15.1)	8 (11.0)	5 (6.8)	1 (1.4)	2 (2.7)	0 (0.0)	73
Pharyngeal	2019	17 (27.4)	37 (59.7)	3 (4.8)	1 (1.6)	4 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	62
Pharyngeal	2020	1 (4.5)	8 (36.4)	5 (22.7)	2 (9.1)	4 (18.2)	2 (9.1)	0 (0.0)	0 (0.0)	22
Rectal	2018	5 (13.9)	15 (41.7)	7 (19.4)	6 (16.7)	2 (5.6)	0 (0.0)	1 (2.8)	0 (0.0)	36
Rectal	2019	5 (20.0)	10 (40.0)	2 (8.0)	5 (20.0)	3 (12.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Rectal	2020	2 (14.3)	4 (28.6)	6 (42.9)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	14

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	246 (69.1)	8 (2.2)	2 (0.6)	2 (0.6)	98 (27.5)	356
Genital	2019	215 (59.7)	4 (1.1)	3 (0.8)	12 (3.3)	126 (35.0)	360
Genital	2020	59 (47.2)	7 (5.6)	1 (0.8)	14 (11.2)	44 (35.2)	125
Pharyngeal	2018	48 (65.8)	3 (4.1)	1 (1.4)	1 (1.4)	20 (27.4)	73
Pharyngeal	2019	31 (50.0)	3 (4.8)	0 (0.0)	2 (3.2)	26 (41.9)	62
Pharyngeal	2020	10 (45.5)	0 (0.0)	0 (0.0)	2 (9.1)	10 (45.5)	22
Rectal	2018	27 (75.0)	1 (2.8)	0 (0.0)	1 (2.8)	7 (19.4)	36
Rectal	2019	14 (56.0)	0 (0.0)	0 (0.0)	1 (4.0)	10 (40.0)	25
Rectal	2020	8 (57.1)	0 (0.0)	1 (7.1)	3 (21.4)	2 (14.3)	14

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	3 (5.3)	25 (10.3)	2 (3.6)	30
Genital	2019	4 (7.8)	19 (7.6)	0 (0.0)	23
Genital	2020	7 (28.0)	10 (11.6)	4 (30.8)	21
Pharyngeal	2018	3 (11.5)	2 (9.1)	3 (12.0)	8
Pharyngeal	2019	2 (11.8)	0 (0.0)	2 (6.7)	4
Pharyngeal	2020	6 (54.5)	0 (0.0)	0 (0.0)	6
Rectal	2018	3 (10.3)	0 (0.0)	0 (0.0)	3
Rectal	2019	3 (15.8)	0 (0.0)	0 (0.0)	3
Rectal	2020	1 (8.3)	0 (0.0)	1 (50.0)	2

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	12 (21.1)	76 (31.3)	12 (21.4)	100
Genital	2019	26 (51.0)	88 (35.3)	24 (40.0)	138
Genital	2020	12 (48.0)	42 (48.8)	3 (23.1)	57
Pharyngeal	2018	8 (30.8)	10 (45.5)	3 (12.0)	21
Pharyngeal	2019	8 (47.1)	6 (40.0)	14 (46.7)	28
Pharyngeal	2020	6 (54.5)	2 (40.0)	4 (80.0)	12
Rectal	2018	6 (20.7)	0 (0.0)	2 (28.6)	8
Rectal	2019	9 (47.4)	0 (0.0)	2 (33.3)	11
Rectal	2020	3 (25.0)	0 (0.0)	2 (100.0)	5

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 µg/ml.


Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	3 (13.6)	6 (27.3)	4 (18.2)	3 (13.6)	2 (9.1)	2 (9.1)	2 (9.1)	0 (0)	0 (0)	0 (0)	0 (0)	22
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	1 (33.3)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	2 (50.0)	1 (25.0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	0 (0)	4
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure B. Percentage of Female Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	16 (72.7)	1 (4.5)	5 (22.7)	0 (0)	0 (0)	0 (0)	22
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	2 (66.7)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	3 (75.0)	0 (0)	1 (25.0)	0 (0)	0 (0)	0 (0)	4
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	3	19	0	22
Genital	2019	0	0	0	0
Genital	2020	0	0	0	0
Pharyngeal	2018	2	1	1	4
Pharyngeal	2019	0	0	0	0
Pharyngeal	2020	0	0	0	0
Rectal	2018	4	0	0	4
Rectal	2019	0	0	0	0
Rectal	2020	0	0	0	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	11 (50.0)	8 (36.4)	3 (13.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	3 (75.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	2 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	5 (22.7)	15 (68.2)	2 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	2 (50.0)	1 (25.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	2 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.

Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	20 (90.9)	0 (0.0)	0 (0.0)	1 (4.5)	1 (4.5)	22
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	4
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	3 (75.0)	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)	4
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs $\geq 2.0 \mu\text{g/ml}$. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Kalamazoo, Michigan, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	1 (33.3)	1 (5.3)	0 (0.0)	2
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	1 (50.0)	0 (0.0)	1 (100.0)	2
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	1 (25.0)	0 (0.0)	0 (0.0)	1
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 µg/ml. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	24 (8.0)	66 (22.1)	71 (23.7)	53 (17.7)	25 (8.4)	19 (6.4)	14 (4.7)	16 (5.4)	5 (1.7)	5 (1.7)	1 (0.3)	299
Genital	2019	16 (6.4)	46 (18.5)	58 (23.3)	52 (20.9)	26 (10.4)	17 (6.8)	10 (4.0)	14 (5.6)	5 (2.0)	5 (2.0)	0 (0)	249
Genital	2020	7 (4.2)	38 (22.8)	41 (24.6)	34 (20.4)	19 (11.4)	12 (7.2)	5 (3.0)	5 (3.0)	4 (2.4)	2 (1.2)	0 (0)	167
Pharyngeal	2018	6 (12.0)	20 (40.0)	14 (28.0)	4 (8.0)	2 (4.0)	1 (2.0)	1 (2.0)	2 (4.0)	0 (0)	0 (0)	0 (0)	50
Pharyngeal	2019	9 (16.4)	14 (25.5)	12 (21.8)	11 (20.0)	3 (5.5)	5 (9.1)	0 (0)	1 (1.8)	0 (0)	0 (0)	0 (0)	55
Pharyngeal	2020	1 (2.8)	5 (13.9)	14 (38.9)	9 (25.0)	3 (8.3)	2 (5.6)	1 (2.8)	1 (2.8)	0 (0)	0 (0)	0 (0)	36
Rectal	2018	3 (9.1)	9 (27.3)	9 (27.3)	4 (12.1)	5 (15.2)	1 (3.0)	1 (3.0)	1 (3.0)	0 (0)	0 (0)	0 (0)	33
Rectal	2019	3 (8.3)	11 (30.6)	6 (16.7)	8 (22.2)	5 (13.9)	1 (2.8)	1 (2.8)	1 (2.8)	0 (0)	0 (0)	0 (0)	36
Rectal	2020	1 (5.0)	2 (10.0)	4 (20.0)	7 (35.0)	3 (15.0)	0 (0)	3 (15.0)	0 (0)	0 (0)	0 (0)	0 (0)	20


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	12 (4.0)	129 (43.1)	1 (0.3)	62 (20.7)	68 (22.7)	15 (5.0)	12 (4.0)	299
Genital	2019	2 (0.8)	4 (1.6)	128 (51.4)	0 (0)	48 (19.3)	48 (19.3)	4 (1.6)	15 (6.0)	249
Genital	2020	1 (0.6)	4 (2.4)	86 (51.5)	0 (0)	18 (10.8)	44 (26.3)	3 (1.8)	11 (6.6)	167
Pharyngeal	2018	0 (0)	1 (2.0)	23 (46.0)	1 (2.0)	8 (16.0)	11 (22.0)	3 (6.0)	3 (6.0)	50
Pharyngeal	2019	0 (0)	2 (3.6)	21 (38.2)	0 (0)	14 (25.5)	15 (27.3)	0 (0)	3 (5.5)	55
Pharyngeal	2020	0 (0)	1 (2.8)	9 (25.0)	0 (0)	8 (22.2)	18 (50.0)	0 (0)	0 (0)	36
Rectal	2018	0 (0)	2 (6.1)	5 (15.2)	1 (3.0)	6 (18.2)	14 (42.4)	2 (6.1)	3 (9.1)	33
Rectal	2019	0 (0)	4 (11.1)	2 (5.6)	1 (2.8)	10 (27.8)	18 (50.0)	0 (0)	1 (2.8)	36
Rectal	2020	0 (0)	3 (15.0)	1 (5.0)	0 (0)	3 (15.0)	11 (55.0)	2 (10.0)	0 (0)	20

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (3.7)	7 (25.9)	0 (0)	7 (25.9)	8 (29.6)	2 (7.4)	2 (7.4)	27
Genital	2019	0 (0)	3 (12.5)	7 (29.2)	0 (0)	7 (29.2)	3 (12.5)	4 (16.7)	0 (0)	24
Genital	2020	0 (0)	0 (0)	4 (57.1)	0 (0)	0 (0)	3 (42.9)	0 (0)	0 (0)	7
Pharyngeal	2018	0 (0)	0 (0)	6 (35.3)	0 (0)	3 (17.6)	7 (41.2)	1 (5.9)	0 (0)	17
Pharyngeal	2019	0 (0)	1 (7.7)	4 (30.8)	0 (0)	2 (15.4)	6 (46.2)	0 (0)	0 (0)	13
Pharyngeal	2020	1 (20.0)	0 (0)	0 (0)	0 (0)	2 (40.0)	2 (40.0)	0 (0)	0 (0)	5
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	2
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	2
Rectal	2020	0 (0)	0 (0)	2 (66.7)	0 (0)	0 (0)	1 (33.3)	0 (0)	0 (0)	3

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	102	195	27	324
Genital	2019	71	172	24	267
Genital	2020	59	105	6	170
Pharyngeal	2018	23	26	17	66
Pharyngeal	2019	28	24	13	65
Pharyngeal	2020	22	12	4	38
Rectal	2018	30	0	2	32
Rectal	2019	34	1	2	37
Rectal	2020	19	0	3	22

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	206 (63.0)	90 (27.5)	26 (8.0)	4 (1.2)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	327
Genital	2019	168 (61.5)	77 (28.2)	23 (8.4)	4 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)	273
Genital	2020	132 (75.9)	36 (20.7)	5 (2.9)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	174
Pharyngeal	2018	38 (55.9)	21 (30.9)	6 (8.8)	3 (4.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	68
Pharyngeal	2019	36 (52.9)	26 (38.2)	6 (8.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	68
Pharyngeal	2020	33 (80.5)	7 (17.1)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Rectal	2018	23 (63.9)	7 (19.4)	5 (13.9)	1 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	36
Rectal	2019	17 (44.7)	16 (42.1)	4 (10.5)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	38
Rectal	2020	18 (78.3)	4 (17.4)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	39 (11.9)	201 (61.5)	63 (19.3)	9 (2.8)	12 (3.7)	1 (0.3)	0 (0.0)	2 (0.6)	327
Genital	2019	31 (11.4)	169 (61.9)	52 (19.0)	13 (4.8)	4 (1.5)	4 (1.5)	0 (0.0)	0 (0.0)	273
Genital	2020	29 (16.7)	88 (50.6)	32 (18.4)	22 (12.6)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	174
Pharyngeal	2018	10 (14.7)	38 (55.9)	13 (19.1)	4 (5.9)	2 (2.9)	1 (1.5)	0 (0.0)	0 (0.0)	68
Pharyngeal	2019	9 (13.2)	39 (57.4)	12 (17.6)	2 (2.9)	4 (5.9)	1 (1.5)	0 (0.0)	1 (1.5)	68
Pharyngeal	2020	6 (14.6)	17 (41.5)	6 (14.6)	8 (19.5)	1 (2.4)	0 (0.0)	3 (7.3)	0 (0.0)	41
Rectal	2018	3 (8.3)	26 (72.2)	5 (13.9)	0 (0.0)	1 (2.8)	1 (2.8)	0 (0.0)	0 (0.0)	36
Rectal	2019	5 (13.2)	20 (52.6)	10 (26.3)	2 (5.3)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	38
Rectal	2020	6 (26.1)	11 (47.8)	1 (4.3)	4 (17.4)	0 (0.0)	0 (0.0)	1 (4.3)	0 (0.0)	23

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	205 (62.7)	3 (0.9)	11 (3.4)	13 (4.0)	95 (29.1)	327
Genital	2019	162 (59.3)	5 (1.8)	5 (1.8)	13 (4.8)	88 (32.2)	273
Genital	2020	105 (60.3)	3 (1.7)	4 (2.3)	11 (6.3)	51 (29.3)	174
Pharyngeal	2018	44 (64.7)	0 (0.0)	1 (1.5)	2 (2.9)	21 (30.9)	68
Pharyngeal	2019	33 (48.5)	1 (1.5)	1 (1.5)	5 (7.4)	28 (41.2)	68
Pharyngeal	2020	28 (68.3)	2 (4.9)	1 (2.4)	3 (7.3)	7 (17.1)	41
Rectal	2018	20 (55.6)	1 (2.8)	1 (2.8)	1 (2.8)	13 (36.1)	36
Rectal	2019	16 (42.1)	1 (2.6)	0 (0.0)	5 (13.2)	16 (42.1)	38
Rectal	2020	13 (56.5)	0 (0.0)	1 (4.3)	2 (8.7)	7 (30.4)	23

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	8 (7.8)	6 (3.1)	0 (0.0)	14
Genital	2019	3 (4.2)	4 (2.3)	1 (4.2)	8
Genital	2020	2 (3.4)	1 (1.0)	0 (0.0)	3
Pharyngeal	2018	0 (0.0)	3 (11.5)	0 (0.0)	3
Pharyngeal	2019	2 (7.1)	3 (12.5)	1 (7.7)	6
Pharyngeal	2020	2 (9.1)	1 (8.3)	1 (25.0)	4
Rectal	2018	2 (6.7)	0 (0.0)	0 (0.0)	2
Rectal	2019	1 (2.9)	0 (0.0)	0 (0.0)	1
Rectal	2020	1 (5.3)	0 (0.0)	0 (0.0)	1

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	38 (37.3)	61 (31.3)	8 (29.6)	107
Genital	2019	32 (45.1)	55 (32.0)	12 (50.0)	99
Genital	2020	27 (45.8)	32 (30.5)	3 (50.0)	62
Pharyngeal	2018	8 (34.8)	8 (30.8)	6 (35.3)	22
Pharyngeal	2019	13 (46.4)	10 (41.7)	9 (69.2)	32
Pharyngeal	2020	7 (31.8)	0 (0.0)	2 (50.0)	9
Rectal	2018	12 (40.0)	0 (0.0)	0 (0.0)	12
Rectal	2019	18 (52.9)	1 (100.0)	1 (50.0)	20
Rectal	2020	9 (47.4)	0 (0.0)	0 (0.0)	9

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 µg/ml.


Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	3 (9.1)	6 (18.2)	14 (42.4)	7 (21.2)	0 (0)	1 (3.0)	2 (6.1)	0 (0)	0 (0)	0 (0)	0 (0)	33
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	1 (25.0)	1 (25.0)	2 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	1 (33.3)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	0 (0)	3
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure B. Percentage of Female Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	24 (72.7)	0 (0)	0 (0)	9 (27.3)	0 (0)	0 (0)	33
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	1 (25.0)	3 (75.0)	0 (0)	0 (0)	4
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	2 (66.7)	0 (0)	0 (0)	3
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	2
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	12	21	2	35
Genital	2019	0	0	0	0
Genital	2020	0	0	0	0
Pharyngeal	2018	4	0	1	5
Pharyngeal	2019	0	0	0	0
Pharyngeal	2020	0	0	0	0
Rectal	2018	3	0	0	3
Rectal	2019	0	0	0	0
Rectal	2020	0	0	0	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	23 (65.7)	9 (25.7)	1 (2.9)	2 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	35
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	3 (60.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	1 (33.3)	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	14 (40.0)	19 (54.3)	0 (0.0)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.9)	35
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	2 (40.0)	2 (40.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	16 (45.7)	0 (0.0)	1 (2.9)	2 (5.7)	16 (45.7)	35
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	3 (60.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)	5
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (66.7)	3
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	0 (0.0)	1 (4.8)	0 (0.0)	1
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs $\geq 2.0 \mu\text{g/ml}$. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Miami, Florida, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	7 (58.3)	10 (47.6)	1 (50.0)	18
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	2 (50.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	2 (66.7)	0 (0.0)	0 (0.0)	2
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 $\mu\text{g/ml}$. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	3 (7.3)	8 (19.5)	13 (31.7)	5 (12.2)	3 (7.3)	2 (4.9)	0 (0)	4 (9.8)	0 (0)	2 (4.9)	1 (2.4)	41
Genital	2019	2 (4.2)	5 (10.4)	14 (29.2)	8 (16.7)	3 (6.3)	3 (6.3)	6 (12.5)	3 (6.3)	3 (6.3)	1 (2.1)	0 (0)	48
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	2 (25.0)	1 (12.5)	4 (50.0)	1 (12.5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8
Pharyngeal	2019	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	6 (54.5)	4 (36.4)	0 (0)	0 (0)	0 (0)	1 (9.1)	0 (0)	0 (0)	0 (0)	11
Rectal	2019	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	3 (75.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure B. Percentage of Female Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	1 (2.4)	1 (2.4)	12 (29.3)	0 (0)	15 (36.6)	4 (9.8)	1 (2.4)	7 (17.1)	41
Genital	2019	1 (2.1)	0 (0)	30 (62.5)	0 (0)	14 (29.2)	1 (2.1)	1 (2.1)	1 (2.1)	48
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	1 (12.5)	0 (0)	5 (62.5)	2 (25.0)	0 (0)	0 (0)	8
Pharyngeal	2019	1 (50.0)	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	9 (81.8)	2 (18.2)	0 (0)	0 (0)	11
Rectal	2019	1 (25.0)	0 (0)	1 (25.0)	0 (0)	2 (50.0)	0 (0)	0 (0)	0 (0)	4
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	19	13	0	32
Genital	2019	11	24	0	35
Genital	2020	0	0	0	0
Pharyngeal	2018	6	1	0	7
Pharyngeal	2019	1	0	0	1
Pharyngeal	2020	0	0	0	0
Rectal	2018	9	2	0	11
Rectal	2019	2	0	0	2
Rectal	2020	0	0	0	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	32 (78.0)	8 (19.5)	1 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Genital	2019	37 (77.1)	8 (16.7)	3 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	48
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	4 (50.0)	2 (25.0)	1 (12.5)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2019	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	5 (45.5)	1 (9.1)	2 (18.2)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2019	3 (75.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	8 (19.5)	26 (63.4)	3 (7.3)	1 (2.4)	0 (0.0)	0 (0.0)	2 (4.9)	1 (2.4)	41
Genital	2019	5 (10.4)	37 (77.1)	4 (8.3)	2 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	48
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	1 (12.5)	6 (75.0)	0 (0.0)	0 (0.0)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2019	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	5 (45.5)	1 (9.1)	1 (9.1)	3 (27.3)	0 (0.0)	1 (9.1)	0 (0.0)	11
Rectal	2019	0 (0.0)	2 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	24 (58.5)	0 (0.0)	0 (0.0)	1 (2.4)	16 (39.0)	41
Genital	2019	27 (56.3)	0 (0.0)	0 (0.0)	2 (4.2)	19 (39.6)	48
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	3 (37.5)	0 (0.0)	0 (0.0)	0 (0.0)	5 (62.5)	8
Pharyngeal	2019	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	4 (36.4)	1 (9.1)	0 (0.0)	0 (0.0)	6 (54.5)	11
Rectal	2019	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (75.0)	4
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	2 (10.5)	0 (0.0)	0 (0.0)	2
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	1 (16.7)	0 (0.0)	0 (0.0)	1
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	4 (44.4)	0 (0.0)	0 (0.0)	4
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs $\geq 2.0 \mu\text{g/ml}$. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	11 (57.9)	1 (7.7)	0 (0.0)	12
Genital	2019	8 (72.7)	5 (20.8)	0 (0.0)	13
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	3 (50.0)	1 (100.0)	0 (0.0)	4
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	5 (55.6)	1 (50.0)	0 (0.0)	6
Rectal	2019	2 (100.0)	0 (0.0)	0 (0.0)	2
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 $\mu\text{g/ml}$. Site participated in eGISP during 2018-2019. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	4 (7.3)	12 (21.8)	7 (12.7)	12 (21.8)	3 (5.5)	6 (10.9)	3 (5.5)	3 (5.5)	2 (3.6)	2 (3.6)	1 (1.8)	55
Genital	2019	6 (5.0)	20 (16.5)	27 (22.3)	24 (19.8)	16 (13.2)	16 (13.2)	2 (1.7)	5 (4.1)	4 (3.3)	0 (0)	1 (0.8)	121
Genital	2020	3 (3.4)	12 (13.6)	18 (20.5)	17 (19.3)	10 (11.4)	10 (11.4)	5 (5.7)	6 (6.8)	4 (4.5)	3 (3.4)	0 (0)	88
Pharyngeal	2018	0 (0)	2 (50.0)	1 (25.0)	0 (0)	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	0 (0)	0 (0)	4
Pharyngeal	2019	1 (8.3)	0 (0)	1 (8.3)	4 (33.3)	4 (33.3)	2 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	12
Pharyngeal	2020	0 (0)	2 (33.3)	1 (16.7)	1 (16.7)	1 (16.7)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6
Rectal	2018	0 (0)	1 (14.3)	3 (42.9)	2 (28.6)	0 (0)	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	7
Rectal	2019	0 (0)	2 (20.0)	2 (20.0)	0 (0)	4 (40.0)	0 (0)	1 (10.0)	1 (10.0)	0 (0)	0 (0)	0 (0)	10
Rectal	2020	0 (0)	1 (14.3)	4 (57.1)	1 (14.3)	0 (0)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	38 (69.1)	0 (0)	12 (21.8)	3 (5.5)	0 (0)	2 (3.6)	55
Genital	2019	0 (0)	2 (1.7)	81 (66.9)	0 (0)	31 (25.6)	6 (5.0)	0 (0)	1 (0.8)	121
Genital	2020	1 (1.1)	1 (1.1)	68 (77.3)	0 (0)	14 (15.9)	4 (4.5)	0 (0)	0 (0)	88
Pharyngeal	2018	0 (0)	0 (0)	1 (25.0)	0 (0)	3 (75.0)	0 (0)	0 (0)	0 (0)	4
Pharyngeal	2019	1 (8.3)	0 (0)	6 (50.0)	0 (0)	5 (41.7)	0 (0)	0 (0)	0 (0)	12
Pharyngeal	2020	0 (0)	1 (16.7)	3 (50.0)	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (16.7)	6
Rectal	2018	0 (0)	0 (0)	2 (28.6)	0 (0)	3 (42.9)	2 (28.6)	0 (0)	0 (0)	7
Rectal	2019	0 (0)	0 (0)	3 (30.0)	0 (0)	6 (60.0)	1 (10.0)	0 (0)	0 (0)	10
Rectal	2020	0 (0)	0 (0)	1 (14.3)	0 (0)	5 (71.4)	1 (14.3)	0 (0)	0 (0)	7

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Genital	2019	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Genital	2020	0 (0)	0 (0)	2 (66.7)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	2018	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	23	32	1	56
Genital	2019	50	70	1	121
Genital	2020	22	64	3	89
Pharyngeal	2018	3	1	1	5
Pharyngeal	2019	10	2	2	14
Pharyngeal	2020	5	1	0	6
Rectal	2018	6	1	1	8
Rectal	2019	9	1	0	10
Rectal	2020	5	2	0	7

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	37 (66.1)	18 (32.1)	1 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	56
Genital	2019	77 (62.6)	43 (35.0)	1 (0.8)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	123
Genital	2020	53 (58.2)	32 (35.2)	4 (4.4)	2 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	91
Pharyngeal	2018	1 (20.0)	3 (60.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2019	7 (50.0)	6 (42.9)	0 (0.0)	0 (0.0)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2020	4 (66.7)	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Rectal	2018	5 (62.5)	1 (12.5)	1 (12.5)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Rectal	2019	7 (70.0)	3 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2020	4 (57.1)	3 (42.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	7 (12.5)	34 (60.7)	10 (17.9)	3 (5.4)	2 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)	56
Genital	2019	19 (15.4)	80 (65.0)	11 (8.9)	8 (6.5)	4 (3.3)	1 (0.8)	0 (0.0)	0 (0.0)	123
Genital	2020	19 (20.9)	39 (42.9)	7 (7.7)	14 (15.4)	12 (13.2)	0 (0.0)	0 (0.0)	0 (0.0)	91
Pharyngeal	2018	1 (20.0)	0 (0.0)	4 (80.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2019	1 (7.1)	8 (57.1)	2 (14.3)	2 (14.3)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	14
Pharyngeal	2020	0 (0.0)	4 (66.7)	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Rectal	2018	1 (12.5)	3 (37.5)	2 (25.0)	2 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Rectal	2019	0 (0.0)	8 (80.0)	0 (0.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2020	1 (14.3)	4 (57.1)	0 (0.0)	1 (14.3)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	7

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	47 (83.9)	0 (0.0)	0 (0.0)	1 (1.8)	8 (14.3)	56
Genital	2019	78 (63.4)	2 (1.6)	1 (0.8)	5 (4.1)	37 (30.1)	123
Genital	2020	39 (42.9)	13 (14.3)	3 (3.3)	7 (7.7)	29 (31.9)	91
Pharyngeal	2018	4 (80.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)	5
Pharyngeal	2019	6 (42.9)	1 (7.1)	0 (0.0)	1 (7.1)	6 (42.9)	14
Pharyngeal	2020	3 (50.0)	1 (16.7)	0 (0.0)	1 (16.7)	1 (16.7)	6
Rectal	2018	3 (37.5)	0 (0.0)	0 (0.0)	1 (12.5)	4 (50.0)	8
Rectal	2019	4 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	6 (60.0)	10
Rectal	2020	3 (42.9)	0 (0.0)	1 (14.3)	0 (0.0)	3 (42.9)	7

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	2 (8.7)	0 (0.0)	0 (0.0)	2
Genital	2019	1 (2.0)	4 (5.7)	0 (0.0)	5
Genital	2020	1 (4.5)	11 (17.2)	0 (0.0)	12
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	1 (50.0)	0 (0.0)	1
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	1 (20.0)	0 (0.0)	0 (0.0)	1

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	7 (30.4)	2 (6.3)	0 (0.0)	9
Genital	2019	22 (44.0)	18 (25.7)	0 (0.0)	40
Genital	2020	10 (45.5)	24 (37.5)	1 (33.3)	35
Pharyngeal	2018	1 (33.3)	0 (0.0)	0 (0.0)	1
Pharyngeal	2019	6 (60.0)	0 (0.0)	1 (50.0)	7
Pharyngeal	2020	2 (40.0)	0 (0.0)	0 (0.0)	2
Rectal	2018	4 (66.7)	1 (100.0)	0 (0.0)	5
Rectal	2019	6 (66.7)	0 (0.0)	0 (0.0)	6
Rectal	2020	2 (40.0)	1 (50.0)	0 (0.0)	3


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs \geq 1.0 μ g/ml.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	3 (1.9)	28 (18.1)	40 (25.8)	25 (16.1)	20 (12.9)	11 (7.1)	13 (8.4)	7 (4.5)	2 (1.3)	5 (3.2)	1 (0.6)	155
Genital	2019	4 (2.6)	23 (14.7)	37 (23.7)	35 (22.4)	19 (12.2)	13 (8.3)	7 (4.5)	8 (5.1)	6 (3.8)	3 (1.9)	1 (0.6)	156
Genital	2020	4 (2.4)	21 (12.8)	37 (22.6)	30 (18.3)	27 (16.5)	15 (9.1)	11 (6.7)	8 (4.9)	7 (4.3)	3 (1.8)	1 (0.6)	164
Pharyngeal	2018	1 (2.4)	13 (31.7)	14 (34.1)	6 (14.6)	5 (12.2)	1 (2.4)	0 (0)	1 (2.4)	0 (0)	0 (0)	0 (0)	41
Pharyngeal	2019	5 (6.9)	15 (20.8)	15 (20.8)	16 (22.2)	7 (9.7)	6 (8.3)	5 (6.9)	3 (4.2)	0 (0)	0 (0)	0 (0)	72
Pharyngeal	2020	0 (0)	8 (32.0)	6 (24.0)	4 (16.0)	4 (16.0)	0 (0)	1 (4.0)	1 (4.0)	1 (4.0)	0 (0)	0 (0)	25
Rectal	2018	6 (6.3)	33 (34.4)	25 (26.0)	19 (19.8)	8 (8.3)	1 (1.0)	1 (1.0)	1 (1.0)	1 (1.0)	0 (0)	1 (1.0)	96
Rectal	2019	7 (6.6)	20 (18.9)	23 (21.7)	21 (19.8)	16 (15.1)	9 (8.5)	7 (6.6)	1 (0.9)	0 (0)	1 (0.9)	1 (0.9)	106
Rectal	2020	2 (1.8)	29 (25.9)	30 (26.8)	25 (22.3)	8 (7.1)	8 (7.1)	4 (3.6)	3 (2.7)	2 (1.8)	1 (0.9)	0 (0)	112


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	12 (7.7)	12 (7.7)	2 (1.3)	37 (23.9)	85 (54.8)	1 (0.6)	6 (3.9)	155
Genital	2019	1 (0.6)	19 (12.2)	13 (8.3)	1 (0.6)	30 (19.2)	90 (57.7)	0 (0)	2 (1.3)	156
Genital	2020	0 (0)	11 (6.7)	19 (11.6)	2 (1.2)	31 (18.9)	97 (59.1)	0 (0)	4 (2.4)	164
Pharyngeal	2018	1 (2.4)	1 (2.4)	0 (0)	1 (2.4)	8 (19.5)	29 (70.7)	0 (0)	1 (2.4)	41
Pharyngeal	2019	0 (0)	4 (5.6)	5 (6.9)	0 (0)	15 (20.8)	48 (66.7)	0 (0)	0 (0)	72
Pharyngeal	2020	0 (0)	8 (32.0)	0 (0)	0 (0)	2 (8.0)	15 (60.0)	0 (0)	0 (0)	25
Rectal	2018	1 (1.0)	12 (12.5)	1 (1.0)	4 (4.2)	15 (15.6)	62 (64.6)	0 (0)	1 (1.0)	96
Rectal	2019	1 (0.9)	15 (14.2)	3 (2.8)	0 (0)	14 (13.2)	72 (67.9)	0 (0)	1 (0.9)	106
Rectal	2020	0 (0)	20 (17.9)	4 (3.6)	3 (2.7)	14 (12.5)	69 (61.6)	0 (0)	2 (1.8)	112

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (10.0)	0 (0)	0 (0)	2 (20.0)	7 (70.0)	0 (0)	0 (0)	10
Genital	2019	0 (0)	0 (0)	1 (11.1)	0 (0)	0 (0)	8 (88.9)	0 (0)	0 (0)	9
Genital	2020	0 (0)	0 (0)	1 (14.3)	0 (0)	1 (14.3)	5 (71.4)	0 (0)	0 (0)	7
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (100.0)	0 (0)	0 (0)	3
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	2
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (100.0)	0 (0)	0 (0)	4
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	65	65	10	140
Genital	2019	82	59	9	150
Genital	2020	84	69	6	159
Pharyngeal	2018	29	1	1	31
Pharyngeal	2019	52	2	3	57
Pharyngeal	2020	18	1	0	19
Rectal	2018	69	2	2	73
Rectal	2019	67	0	4	71
Rectal	2020	75	0	0	75

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	127 (77.0)	22 (13.3)	13 (7.9)	3 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	165
Genital	2019	107 (64.8)	43 (26.1)	14 (8.5)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	165
Genital	2020	110 (64.0)	50 (29.1)	12 (7.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	172
Pharyngeal	2018	31 (68.9)	9 (20.0)	3 (6.7)	2 (4.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	45
Pharyngeal	2019	49 (63.6)	21 (27.3)	6 (7.8)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Pharyngeal	2020	18 (69.2)	5 (19.2)	3 (11.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	26
Rectal	2018	77 (75.5)	21 (20.6)	4 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	102
Rectal	2019	70 (61.9)	37 (32.7)	4 (3.5)	2 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2020	71 (62.8)	36 (31.9)	6 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	8 (4.8)	137 (83.0)	10 (6.1)	1 (0.6)	7 (4.2)	0 (0.0)	2 (1.2)	0 (0.0)	165
Genital	2019	13 (7.9)	127 (77.0)	7 (4.2)	10 (6.1)	8 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	165
Genital	2020	7 (4.1)	107 (62.2)	20 (11.6)	23 (13.4)	14 (8.1)	0 (0.0)	0 (0.0)	1 (0.6)	172
Pharyngeal	2018	3 (6.7)	36 (80.0)	2 (4.4)	0 (0.0)	4 (8.9)	0 (0.0)	0 (0.0)	0 (0.0)	45
Pharyngeal	2019	6 (7.8)	59 (76.6)	0 (0.0)	2 (2.6)	10 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Pharyngeal	2020	3 (11.5)	12 (46.2)	7 (26.9)	3 (11.5)	1 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	26
Rectal	2018	2 (2.0)	80 (78.4)	7 (6.9)	2 (2.0)	11 (10.8)	0 (0.0)	0 (0.0)	0 (0.0)	102
Rectal	2019	6 (5.3)	83 (73.5)	4 (3.5)	9 (8.0)	11 (9.7)	0 (0.0)	0 (0.0)	0 (0.0)	113
Rectal	2020	5 (4.4)	62 (54.9)	13 (11.5)	20 (17.7)	13 (11.5)	0 (0.0)	0 (0.0)	0 (0.0)	113

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	85 (51.5)	1 (0.6)	0 (0.0)	12 (7.3)	67 (40.6)	165
Genital	2019	66 (40.0)	2 (1.2)	6 (3.6)	16 (9.7)	75 (45.5)	165
Genital	2020	95 (55.2)	4 (2.3)	7 (4.1)	9 (5.2)	57 (33.1)	172
Pharyngeal	2018	17 (37.8)	0 (0.0)	0 (0.0)	2 (4.4)	26 (57.8)	45
Pharyngeal	2019	30 (39.0)	2 (2.6)	5 (6.5)	9 (11.7)	31 (40.3)	77
Pharyngeal	2020	9 (34.6)	1 (3.8)	0 (0.0)	3 (11.5)	13 (50.0)	26
Rectal	2018	55 (53.9)	0 (0.0)	1 (1.0)	7 (6.9)	39 (38.2)	102
Rectal	2019	54 (47.8)	4 (3.5)	6 (5.3)	9 (8.0)	40 (35.4)	113
Rectal	2020	51 (45.1)	2 (1.8)	3 (2.7)	11 (9.7)	46 (40.7)	113

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	7 (10.8)	0 (0.0)	0 (0.0)	7
Genital	2019	7 (8.5)	0 (0.0)	0 (0.0)	7
Genital	2020	12 (14.3)	2 (2.9)	0 (0.0)	14
Pharyngeal	2018	1 (3.4)	0 (0.0)	0 (0.0)	1
Pharyngeal	2019	7 (13.5)	0 (0.0)	0 (0.0)	7
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	7 (10.1)	0 (0.0)	0 (0.0)	7
Rectal	2019	8 (11.9)	0 (0.0)	0 (0.0)	8
Rectal	2020	9 (12.0)	0 (0.0)	0 (0.0)	9

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	30 (46.2)	32 (49.2)	5 (50.0)	67
Genital	2019	44 (53.7)	31 (52.5)	7 (77.8)	82
Genital	2020	34 (40.5)	25 (36.2)	2 (33.3)	61
Pharyngeal	2018	16 (55.2)	1 (100.0)	0 (0.0)	17
Pharyngeal	2019	32 (61.5)	0 (0.0)	1 (33.3)	33
Pharyngeal	2020	12 (66.7)	0 (0.0)	0 (0.0)	12
Rectal	2018	31 (44.9)	0 (0.0)	0 (0.0)	31
Rectal	2019	29 (43.3)	0 (0.0)	2 (50.0)	31
Rectal	2020	35 (46.7)	0 (0.0)	0 (0.0)	35


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs \geq 1.0 μ g/ml.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	26 (8.7)	57 (19.0)	70 (23.3)	45 (15.0)	26 (8.7)	19 (6.3)	9 (3.0)	23 (7.7)	11 (3.7)	9 (3.0)	5 (1.7)	300
Genital	2019	21 (7.0)	66 (22.0)	72 (24.0)	47 (15.7)	36 (12.0)	14 (4.7)	6 (2.0)	17 (5.7)	13 (4.3)	7 (2.3)	1 (0.3)	300
Genital	2020	14 (7.7)	32 (17.6)	50 (27.5)	36 (19.8)	20 (11.0)	4 (2.2)	6 (3.3)	7 (3.8)	4 (2.2)	3 (1.6)	6 (3.3)	182
Pharyngeal	2018	4 (7.7)	15 (28.8)	22 (42.3)	5 (9.6)	2 (3.8)	0 (0)	3 (5.8)	1 (1.9)	0 (0)	0 (0)	0 (0)	52
Pharyngeal	2019	1 (3.2)	10 (32.3)	8 (25.8)	5 (16.1)	1 (3.2)	3 (9.7)	1 (3.2)	1 (3.2)	0 (0)	1 (3.2)	0 (0)	31
Pharyngeal	2020	1 (9.1)	3 (27.3)	5 (45.5)	1 (9.1)	1 (9.1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	11
Rectal	2018	4 (9.8)	11 (26.8)	7 (17.1)	9 (22.0)	6 (14.6)	2 (4.9)	1 (2.4)	1 (2.4)	0 (0)	0 (0)	0 (0)	41
Rectal	2019	4 (8.2)	11 (22.4)	17 (34.7)	8 (16.3)	5 (10.2)	1 (2.0)	2 (4.1)	1 (2.0)	0 (0)	0 (0)	0 (0)	49
Rectal	2020	0 (0)	4 (19.0)	7 (33.3)	4 (19.0)	2 (9.5)	0 (0)	0 (0)	3 (14.3)	1 (4.8)	0 (0)	0 (0)	21


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	7 (2.3)	196 (65.3)	1 (0.3)	39 (13.0)	15 (5.0)	13 (4.3)	29 (9.7)	300
Genital	2019	0 (0)	1 (0.3)	214 (71.3)	0 (0)	25 (8.3)	19 (6.3)	13 (4.3)	28 (9.3)	300
Genital	2020	0 (0)	1 (0.5)	121 (66.5)	0 (0)	14 (7.7)	11 (6.0)	9 (4.9)	26 (14.3)	182
Pharyngeal	2018	1 (1.9)	2 (3.8)	17 (32.7)	0 (0)	19 (36.5)	5 (9.6)	3 (5.8)	5 (9.6)	52
Pharyngeal	2019	0 (0)	0 (0)	14 (45.2)	0 (0)	10 (32.3)	3 (9.7)	0 (0)	4 (12.9)	31
Pharyngeal	2020	0 (0)	0 (0)	4 (36.4)	0 (0)	6 (54.5)	0 (0)	1 (9.1)	0 (0)	11
Rectal	2018	0 (0)	4 (9.8)	11 (26.8)	0 (0)	14 (34.1)	4 (9.8)	4 (9.8)	4 (9.8)	41
Rectal	2019	0 (0)	3 (6.1)	13 (26.5)	0 (0)	22 (44.9)	6 (12.2)	2 (4.1)	3 (6.1)	49
Rectal	2020	0 (0)	1 (4.8)	10 (47.6)	0 (0)	5 (23.8)	1 (4.8)	4 (19.0)	0 (0)	21

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (5.6)	12 (66.7)	0 (0)	1 (5.6)	2 (11.1)	1 (5.6)	1 (5.6)	18
Genital	2019	0 (0)	1 (11.1)	3 (33.3)	0 (0)	1 (11.1)	2 (22.2)	1 (11.1)	1 (11.1)	9
Genital	2020	0 (0)	0 (0)	4 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	1
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	172	126	18	316
Genital	2019	108	189	9	306
Genital	2020	57	123	3	183
Pharyngeal	2018	22	30	1	53
Pharyngeal	2019	30	1	0	31
Pharyngeal	2020	9	0	0	9
Rectal	2018	28	12	0	40
Rectal	2019	46	1	0	47
Rectal	2020	20	1	0	21

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	203 (63.8)	49 (15.4)	52 (16.4)	14 (4.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	318
Genital	2019	230 (74.4)	57 (18.4)	16 (5.2)	6 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	309
Genital	2020	154 (82.8)	29 (15.6)	2 (1.1)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	186
Pharyngeal	2018	30 (56.6)	11 (20.8)	12 (22.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	53
Pharyngeal	2019	22 (71.0)	6 (19.4)	3 (9.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31
Pharyngeal	2020	8 (72.7)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2018	28 (68.3)	9 (22.0)	4 (9.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	41
Rectal	2019	32 (65.3)	11 (22.4)	5 (10.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	49
Rectal	2020	18 (85.7)	3 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	21

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	61 (19.2)	145 (45.6)	42 (13.2)	32 (10.1)	11 (3.5)	6 (1.9)	13 (4.1)	8 (2.5)	318
Genital	2019	40 (12.9)	202 (65.4)	33 (10.7)	20 (6.5)	7 (2.3)	4 (1.3)	1 (0.3)	2 (0.6)	309
Genital	2020	12 (6.5)	69 (37.1)	49 (26.3)	37 (19.9)	8 (4.3)	8 (4.3)	1 (0.5)	2 (1.1)	186
Pharyngeal	2018	6 (11.3)	24 (45.3)	8 (15.1)	11 (20.8)	2 (3.8)	0 (0.0)	2 (3.8)	0 (0.0)	53
Pharyngeal	2019	4 (12.9)	17 (54.8)	6 (19.4)	3 (9.7)	1 (3.2)	0 (0.0)	0 (0.0)	0 (0.0)	31
Pharyngeal	2020	0 (0.0)	6 (54.5)	2 (18.2)	1 (9.1)	2 (18.2)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2018	8 (19.5)	25 (61.0)	2 (4.9)	3 (7.3)	3 (7.3)	0 (0.0)	0 (0.0)	0 (0.0)	41
Rectal	2019	3 (6.1)	28 (57.1)	9 (18.4)	3 (6.1)	6 (12.2)	0 (0.0)	0 (0.0)	0 (0.0)	49
Rectal	2020	2 (9.5)	8 (38.1)	5 (23.8)	5 (23.8)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	184 (57.9)	9 (2.8)	3 (0.9)	9 (2.8)	113 (35.5)	318
Genital	2019	142 (46.0)	1 (0.3)	5 (1.6)	23 (7.4)	138 (44.7)	309
Genital	2020	91 (48.9)	2 (1.1)	3 (1.6)	26 (14.0)	64 (34.4)	186
Pharyngeal	2018	36 (67.9)	0 (0.0)	0 (0.0)	1 (1.9)	16 (30.2)	53
Pharyngeal	2019	14 (45.2)	0 (0.0)	1 (3.2)	3 (9.7)	13 (41.9)	31
Pharyngeal	2020	6 (54.5)	1 (9.1)	0 (0.0)	1 (9.1)	3 (27.3)	11
Rectal	2018	28 (68.3)	0 (0.0)	0 (0.0)	2 (4.9)	11 (26.8)	41
Rectal	2019	21 (42.9)	2 (4.1)	1 (2.0)	5 (10.2)	20 (40.8)	49
Rectal	2020	11 (52.4)	0 (0.0)	1 (4.8)	2 (9.5)	7 (33.3)	21

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	26 (15.1)	11 (8.7)	1 (5.6)	38
Genital	2019	6 (5.6)	7 (3.7)	1 (11.1)	14
Genital	2020	8 (14.0)	10 (8.1)	0 (0.0)	18
Pharyngeal	2018	1 (4.5)	3 (10.0)	0 (0.0)	4
Pharyngeal	2019	1 (3.3)	0 (0.0)	0 (0.0)	1
Pharyngeal	2020	2 (22.2)	0 (0.0)	0 (0.0)	2
Rectal	2018	3 (10.7)	0 (0.0)	0 (0.0)	3
Rectal	2019	6 (13.0)	0 (0.0)	0 (0.0)	6
Rectal	2020	1 (5.0)	0 (0.0)	0 (0.0)	1

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	64 (37.2)	51 (40.5)	7 (38.9)	122
Genital	2019	63 (58.3)	95 (50.3)	2 (22.2)	160
Genital	2020	29 (50.9)	57 (46.3)	2 (66.7)	88
Pharyngeal	2018	9 (40.9)	8 (26.7)	0 (0.0)	17
Pharyngeal	2019	15 (50.0)	1 (100.0)	0 (0.0)	16
Pharyngeal	2020	4 (44.4)	0 (0.0)	0 (0.0)	4
Rectal	2018	10 (35.7)	3 (25.0)	0 (0.0)	13
Rectal	2019	24 (52.2)	0 (0.0)	0 (0.0)	24
Rectal	2020	8 (40.0)	1 (100.0)	0 (0.0)	9

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 µg/ml.


Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	17 (5.7)	69 (23.0)	59 (19.7)	61 (20.3)	30 (10.0)	22 (7.3)	16 (5.3)	10 (3.3)	9 (3.0)	5 (1.7)	2 (0.7)	300
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	5 (11.4)	11 (25.0)	11 (25.0)	9 (20.5)	5 (11.4)	1 (2.3)	1 (2.3)	0 (0)	1 (2.3)	0 (0)	0 (0)	44
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	7 (11.7)	21 (35.0)	15 (25.0)	8 (13.3)	4 (6.7)	1 (1.7)	3 (5.0)	1 (1.7)	0 (0)	0 (0)	0 (0)	60

Note: Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure B. Percentage of Female Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	19 (23.8)	31 (38.8)	17 (21.3)	5 (6.3)	3 (3.8)	2 (2.5)	2 (2.5)	0 (0)	0 (0)	0 (0)	1 (1.3)	80
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	5 (35.7)	4 (28.6)	1 (7.1)	3 (21.4)	0 (0)	1 (7.1)	0 (0)	0 (0)	0 (0)	0 (0)	14
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	3 (50.0)	2 (33.3)	0 (0)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6

Note: Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	2 (0.7)	2 (0.7)	108 (36.0)	3 (1.0)	66 (22.0)	116 (38.7)	2 (0.7)	1 (0.3)	300
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	1 (2.3)	2 (4.5)	11 (25.0)	0 (0)	16 (36.4)	14 (31.8)	0 (0)	0 (0)	44
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	3 (5.0)	2 (3.3)	5 (8.3)	1 (1.7)	15 (25.0)	34 (56.7)	0 (0)	0 (0)	60

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	2 (2.5)	1 (1.3)	20 (25.0)	0 (0)	22 (27.5)	35 (43.8)	0 (0)	0 (0)	80
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	1 (7.1)	0 (0)	4 (28.6)	0 (0)	2 (14.3)	7 (50.0)	0 (0)	0 (0)	14
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	3 (50.0)	0 (0)	1 (16.7)	2 (33.3)	0 (0)	0 (0)	6

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	0	0	0	0
Genital	2019	0	0	0	0
Genital	2020	91	206	80	377
Pharyngeal	2018	0	0	0	0
Pharyngeal	2019	0	0	0	0
Pharyngeal	2020	34	10	14	58
Rectal	2018	0	0	0	0
Rectal	2019	0	0	0	0
Rectal	2020	59	1	6	66

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	214 (56.3)	117 (30.8)	42 (11.1)	7 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	380
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	20 (34.5)	25 (43.1)	12 (20.7)	1 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	58
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	29 (43.9)	26 (39.4)	10 (15.2)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	66

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	45 (11.8)	264 (69.5)	19 (5.0)	37 (9.7)	11 (2.9)	2 (0.5)	1 (0.3)	1 (0.3)	380
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	4 (6.9)	42 (72.4)	5 (8.6)	5 (8.6)	1 (1.7)	0 (0.0)	0 (0.0)	1 (1.7)	58
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	8 (12.1)	40 (60.6)	6 (9.1)	10 (15.2)	2 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	66

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	261 (68.7)	4 (1.1)	8 (2.1)	16 (4.2)	91 (23.9)	380
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	26 (44.8)	2 (3.4)	0 (0.0)	2 (3.4)	28 (48.3)	58
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	42 (63.6)	0 (0.0)	1 (1.5)	5 (7.6)	18 (27.3)	66

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	2 (2.2)	4 (1.9)	9 (11.3)	15
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	1 (2.9)	0 (0.0)	1 (7.1)	2
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	2 (3.4)	0 (0.0)	0 (0.0)	2

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	40 (44.0)	49 (23.8)	17 (21.3)	106
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	21 (61.8)	2 (20.0)	7 (50.0)	30
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	22 (37.3)	0 (0.0)	1 (16.7)	23

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs ≥ 1.0 $\mu\text{g/ml}$. Site participated in eGISP in 2020. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	2 (0.8)	183 (74.4)	0 (0)	43 (17.5)	7 (2.8)	0 (0)	11 (4.5)	246
Genital	2019	0 (0)	1 (0.5)	146 (73.7)	0 (0)	23 (11.6)	3 (1.5)	0 (0)	25 (12.6)	198
Genital	2020	0 (0)	0 (0)	41 (89.1)	0 (0)	4 (8.7)	0 (0)	0 (0)	1 (2.2)	46
Pharyngeal	2018	0 (0)	0 (0)	3 (21.4)	0 (0)	9 (64.3)	2 (14.3)	0 (0)	0 (0)	14
Pharyngeal	2019	1 (5.0)	0 (0)	8 (40.0)	0 (0)	5 (25.0)	3 (15.0)	0 (0)	3 (15.0)	20
Pharyngeal	2020	0 (0)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	3
Rectal	2018	0 (0)	1 (6.3)	2 (12.5)	0 (0)	13 (81.3)	0 (0)	0 (0)	0 (0)	16
Rectal	2019	0 (0)	0 (0)	15 (51.7)	0 (0)	10 (34.5)	2 (6.9)	1 (3.4)	1 (3.4)	29
Rectal	2020	0 (0)	0 (0)	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	9 (64.3)	0 (0)	5 (35.7)	0 (0)	0 (0)	0 (0)	14
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	1 (33.3)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	3
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1
Rectal	2019	0 (0)	0 (0)	2 (66.7)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	3
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	68	176	14	258
Genital	2019	63	135	0	198
Genital	2020	11	35	0	46
Pharyngeal	2018	9	5	3	17
Pharyngeal	2019	18	1	0	19
Pharyngeal	2020	2	1	0	3
Rectal	2018	15	1	1	17
Rectal	2019	28	1	3	32
Rectal	2020	2	0	0	2

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	195 (75.0)	37 (14.2)	25 (9.6)	3 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	260
Genital	2019	140 (70.7)	42 (21.2)	15 (7.6)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	198
Genital	2020	25 (54.3)	15 (32.6)	6 (13.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	46
Pharyngeal	2018	7 (41.2)	8 (47.1)	1 (5.9)	1 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	17
Pharyngeal	2019	9 (45.0)	9 (45.0)	2 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2020	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2018	8 (47.1)	6 (35.3)	2 (11.8)	1 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	17
Rectal	2019	16 (50.0)	15 (46.9)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	32
Rectal	2020	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	78 (30.0)	135 (51.9)	24 (9.2)	17 (6.5)	5 (1.9)	0 (0.0)	0 (0.0)	1 (0.4)	260
Genital	2019	57 (28.8)	89 (44.9)	13 (6.6)	29 (14.6)	9 (4.5)	1 (0.5)	0 (0.0)	0 (0.0)	198
Genital	2020	5 (10.9)	19 (41.3)	4 (8.7)	15 (32.6)	3 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	46
Pharyngeal	2018	2 (11.8)	11 (64.7)	4 (23.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	17
Pharyngeal	2019	3 (15.0)	9 (45.0)	3 (15.0)	3 (15.0)	2 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2020	0 (0.0)	2 (66.7)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2018	2 (11.8)	8 (47.1)	4 (23.5)	2 (11.8)	1 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)	17
Rectal	2019	2 (6.3)	17 (53.1)	5 (15.6)	7 (21.9)	1 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	32
Rectal	2020	0 (0.0)	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	190 (73.1)	2 (0.8)	3 (1.2)	8 (3.1)	57 (21.9)	260
Genital	2019	140 (70.7)	5 (2.5)	2 (1.0)	9 (4.5)	42 (21.2)	198
Genital	2020	40 (87.0)	2 (4.3)	0 (0.0)	2 (4.3)	2 (4.3)	46
Pharyngeal	2018	15 (88.2)	0 (0.0)	0 (0.0)	0 (0.0)	2 (11.8)	17
Pharyngeal	2019	13 (65.0)	0 (0.0)	1 (5.0)	0 (0.0)	6 (30.0)	20
Pharyngeal	2020	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (66.7)	3
Rectal	2018	10 (58.8)	1 (5.9)	0 (0.0)	0 (0.0)	6 (35.3)	17
Rectal	2019	16 (50.0)	0 (0.0)	0 (0.0)	3 (9.4)	13 (40.6)	32
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (100.0)	2

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	1 (1.5)	5 (2.8)	0 (0.0)	6
Genital	2019	4 (6.3)	6 (4.4)	0 (0.0)	10
Genital	2020	0 (0.0)	3 (8.6)	0 (0.0)	3
Pharyngeal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2019	2 (11.1)	0 (0.0)	0 (0.0)	2
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	1 (6.7)	0 (0.0)	0 (0.0)	1
Rectal	2019	1 (3.6)	0 (0.0)	0 (0.0)	1
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	26 (38.2)	39 (22.2)	0 (0.0)	65
Genital	2019	21 (33.3)	30 (22.2)	0 (0.0)	51
Genital	2020	1 (9.1)	3 (8.6)	0 (0.0)	4
Pharyngeal	2018	1 (11.1)	1 (20.0)	0 (0.0)	2
Pharyngeal	2019	6 (33.3)	0 (0.0)	0 (0.0)	6
Pharyngeal	2020	2 (100.0)	0 (0.0)	0 (0.0)	2
Rectal	2018	5 (33.3)	1 (100.0)	0 (0.0)	6
Rectal	2019	15 (53.6)	0 (0.0)	1 (33.3)	16
Rectal	2020	2 (100.0)	0 (0.0)	0 (0.0)	2

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs \geq 1.0 μ g/ml.


Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	1 (1.4)	9 (12.7)	8 (11.3)	18 (25.4)	12 (16.9)	7 (9.9)	6 (8.5)	6 (8.5)	1 (1.4)	2 (2.8)	1 (1.4)	71
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	2 (11.1)	3 (16.7)	3 (16.7)	3 (16.7)	2 (11.1)	1 (5.6)	1 (5.6)	3 (16.7)	0 (0)	0 (0)	18
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	2 (14.3)	2 (14.3)	1 (7.1)	5 (35.7)	2 (14.3)	0 (0)	0 (0)	1 (7.1)	0 (0)	1 (7.1)	0 (0)	14
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure B. Percentage of Female Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	1 (20.0)	2 (40.0)	0 (0)	0 (0)	1 (20.0)	0 (0)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	5
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	26 (36.6)	0 (0)	29 (40.8)	13 (18.3)	2 (2.8)	1 (1.4)	71
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	0 (0)	2 (11.1)	0 (0)	14 (77.8)	2 (11.1)	0 (0)	0 (0)	18
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	1 (7.1)	1 (7.1)	1 (7.1)	0 (0)	9 (64.3)	2 (14.3)	0 (0)	0 (0)	14
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	1 (20.0)	1 (20.0)	0 (0)	3 (60.0)	0 (0)	0 (0)	0 (0)	5
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2018	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	2
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	1
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	34	35	5	74
Genital	2019	0	0	0	0
Genital	2020	0	0	0	0
Pharyngeal	2018	18	0	2	20
Pharyngeal	2019	0	0	0	0
Pharyngeal	2020	0	0	0	0
Rectal	2018	13	1	1	15
Rectal	2019	0	0	0	0
Rectal	2020	0	0	0	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	47 (61.0)	21 (27.3)	9 (11.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	11 (55.0)	7 (35.0)	2 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	10 (66.7)	1 (6.7)	4 (26.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	7 (9.1)	58 (75.3)	8 (10.4)	2 (2.6)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	2 (10.0)	13 (65.0)	4 (20.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	20
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	9 (60.0)	6 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	55 (71.4)	3 (3.9)	0 (0.0)	4 (5.2)	15 (19.5)	77
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	13 (65.0)	1 (5.0)	0 (0.0)	1 (5.0)	5 (25.0)	20
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	8 (53.3)	0 (0.0)	0 (0.0)	1 (6.7)	6 (40.0)	15
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: Data includes isolates from both male and female participants. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	1 (2.9)	0 (0.0)	0 (0.0)	1
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	1 (5.6)	0 (0.0)	0 (0.0)	1
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.


Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Portland, Oregon, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	9 (26.5)	8 (22.9)	1 (20.0)	18
Genital	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2018	6 (33.3)	0 (0.0)	0 (0.0)	6
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2018	6 (46.2)	0 (0.0)	1 (100.0)	7
Rectal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2020	0 (0.0)	0 (0.0)	0 (0.0)	0


Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs \geq 1.0 μ g/ml. Site participated in eGISP in 2018. Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.

Figure A. Percentage of Male Participants by Age Group and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	< 20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	2018	1 (1.0)	6 (6.3)	19 (19.8)	17 (17.7)	15 (15.6)	13 (13.5)	9 (9.4)	8 (8.3)	6 (6.3)	2 (2.1)	0 (0)	96
Genital	2019	0 (0)	12 (9.2)	22 (16.9)	31 (23.8)	17 (13.1)	19 (14.6)	5 (3.8)	8 (6.2)	7 (5.4)	3 (2.3)	6 (4.6)	130
Genital	2020	3 (3.0)	4 (4.0)	12 (11.9)	24 (23.8)	17 (16.8)	17 (16.8)	8 (7.9)	4 (4.0)	7 (6.9)	2 (2.0)	3 (3.0)	101
Pharyngeal	2018	0 (0)	3 (17.6)	5 (29.4)	3 (17.6)	3 (17.6)	2 (11.8)	1 (5.9)	0 (0)	0 (0)	0 (0)	0 (0)	17
Pharyngeal	2019	0 (0)	0 (0)	2 (28.6)	2 (28.6)	1 (14.3)	2 (28.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7
Pharyngeal	2020	0 (0)	1 (7.1)	5 (35.7)	2 (14.3)	2 (14.3)	1 (7.1)	0 (0)	1 (7.1)	2 (14.3)	0 (0)	0 (0)	14
Rectal	2018	0 (0)	3 (21.4)	2 (14.3)	1 (7.1)	2 (14.3)	4 (28.6)	1 (7.1)	1 (7.1)	0 (0)	0 (0)	0 (0)	14
Rectal	2019	1 (5.6)	6 (33.3)	5 (27.8)	3 (16.7)	1 (5.6)	1 (5.6)	1 (5.6)	0 (0)	0 (0)	0 (0)	0 (0)	18
Rectal	2020	2 (9.1)	2 (9.1)	8 (36.4)	3 (13.6)	3 (13.6)	2 (9.1)	1 (4.5)	0 (0)	0 (0)	1 (4.5)	0 (0)	22


Figure C. Percentage of Male Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	8 (8.3)	18 (18.8)	0 (0)	39 (40.6)	22 (22.9)	0 (0)	9 (9.4)	96
Genital	2019	1 (0.8)	9 (6.9)	22 (16.9)	0 (0)	50 (38.5)	42 (32.3)	0 (0)	6 (4.6)	130
Genital	2020	1 (1.0)	4 (4.0)	27 (26.7)	0 (0)	45 (44.6)	19 (18.8)	0 (0)	5 (5.0)	101
Pharyngeal	2018	0 (0)	2 (11.8)	3 (17.6)	0 (0)	8 (47.1)	4 (23.5)	0 (0)	0 (0)	17
Pharyngeal	2019	0 (0)	0 (0)	1 (14.3)	0 (0)	3 (42.9)	3 (42.9)	0 (0)	0 (0)	7
Pharyngeal	2020	0 (0)	0 (0)	0 (0)	0 (0)	8 (57.1)	5 (35.7)	0 (0)	1 (7.1)	14
Rectal	2018	0 (0)	3 (21.4)	1 (7.1)	0 (0)	5 (35.7)	5 (35.7)	0 (0)	0 (0)	14
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	7 (38.9)	10 (55.6)	0 (0)	1 (5.6)	18
Rectal	2020	0 (0)	3 (13.6)	1 (4.5)	0 (0)	6 (27.3)	11 (50.0)	0 (0)	1 (4.5)	22

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure D. Percentage of Female Participants by Race/Ethnicity and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	2018	0 (0)	0 (0)	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2
Genital	2019	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1
Genital	2020	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1
Pharyngeal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	2019	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1
Pharyngeal	2020	0 (0)	0 (0)	1 (33.3)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	3
Rectal	2018	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2019	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	2020	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1

Note: Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories. AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.


Figure E. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2018	68	28	2	98
Genital	2019	87	43	1	131
Genital	2020	59	42	1	102
Pharyngeal	2018	17	0	0	17
Pharyngeal	2019	7	0	1	8
Pharyngeal	2020	12	2	3	17
Rectal	2018	14	0	0	14
Rectal	2019	17	1	0	18
Rectal	2020	22	0	1	23

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only.


Figure F. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	≤ 0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2018	67 (68.4)	19 (19.4)	11 (11.2)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Genital	2019	74 (56.1)	43 (32.6)	12 (9.1)	3 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	132
Genital	2020	68 (65.4)	29 (27.9)	7 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	104
Pharyngeal	2018	9 (52.9)	6 (35.3)	1 (5.9)	1 (5.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	17
Pharyngeal	2019	4 (50.0)	3 (37.5)	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2020	9 (50.0)	7 (38.9)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2018	11 (78.6)	2 (14.3)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2019	10 (55.6)	7 (38.9)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2020	15 (62.5)	6 (25.0)	3 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24

Note: Data includes isolates from both male and female participants.


Figure G. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	≤ 0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥ 16.0 n (%)	Total
Genital	2018	8 (8.2)	65 (66.3)	7 (7.1)	7 (7.1)	11 (11.2)	0 (0.0)	0 (0.0)	0 (0.0)	98
Genital	2019	12 (9.1)	99 (75.0)	6 (4.5)	4 (3.0)	9 (6.8)	2 (1.5)	0 (0.0)	0 (0.0)	132
Genital	2020	8 (7.7)	71 (68.3)	10 (9.6)	3 (2.9)	10 (9.6)	1 (1.0)	1 (1.0)	0 (0.0)	104
Pharyngeal	2018	0 (0.0)	11 (64.7)	1 (5.9)	1 (5.9)	4 (23.5)	0 (0.0)	0 (0.0)	0 (0.0)	17
Pharyngeal	2019	0 (0.0)	8 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	8
Pharyngeal	2020	0 (0.0)	12 (66.7)	2 (11.1)	2 (11.1)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2018	1 (7.1)	10 (71.4)	1 (7.1)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2019	1 (5.6)	15 (83.3)	1 (5.6)	0 (0.0)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2020	2 (8.3)	14 (58.3)	2 (8.3)	3 (12.5)	3 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	24

Note: Data includes isolates from both male and female participants.


Figure H. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	≤ 0.015 n (%)	0.03-0.06 n (%)	0.125-0.5 n (%)	1.0-2.0 n (%)	≥ 4.0 n (%)	Total
Genital	2018	48 (49.0)	1 (1.0)	1 (1.0)	7 (7.1)	41 (41.8)	98
Genital	2019	46 (34.8)	4 (3.0)	4 (3.0)	10 (7.6)	68 (51.5)	132
Genital	2020	47 (45.2)	4 (3.8)	4 (3.8)	10 (9.6)	39 (37.5)	104
Pharyngeal	2018	6 (35.3)	1 (5.9)	1 (5.9)	1 (5.9)	8 (47.1)	17
Pharyngeal	2019	2 (25.0)	0 (0.0)	0 (0.0)	2 (25.0)	4 (50.0)	8
Pharyngeal	2020	6 (33.3)	1 (5.6)	0 (0.0)	0 (0.0)	11 (61.1)	18
Rectal	2018	9 (64.3)	1 (7.1)	0 (0.0)	1 (7.1)	3 (21.4)	14
Rectal	2019	10 (55.6)	1 (5.6)	0 (0.0)	0 (0.0)	7 (38.9)	18
Rectal	2020	11 (45.8)	1 (4.2)	0 (0.0)	3 (12.5)	9 (37.5)	24

Note: Data includes isolates from both male and female participants.


Figure I. Percentage of *Neisseria gonorrhoeae* Isolates with Elevated Minimum Inhibitory Concentrations (MICs) to Azithromycin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	10 (14.7)	1 (3.6)	0 (0.0)	11
Genital	2019	8 (9.2)	3 (7.0)	0 (0.0)	11
Genital	2020	10 (16.9)	2 (4.8)	0 (0.0)	12
Pharyngeal	2018	4 (23.5)	0 (0.0)	0 (0.0)	4
Pharyngeal	2019	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2020	2 (16.7)	0 (0.0)	0 (0.0)	2
Rectal	2018	2 (14.3)	0 (0.0)	0 (0.0)	2
Rectal	2019	1 (5.9)	0 (0.0)	0 (0.0)	1
Rectal	2020	3 (13.6)	0 (0.0)	0 (0.0)	3

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Azithromycin elevated MICs ≥ 2.0 $\mu\text{g/ml}$.

Figure J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Gender and Gender of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2018-2020



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2018	37 (54.4)	11 (39.3)	0 (0.0)	48
Genital	2019	54 (62.1)	22 (51.2)	1 (100.0)	77
Genital	2020	31 (52.5)	17 (40.5)	0 (0.0)	48
Pharyngeal	2018	9 (52.9)	0 (0.0)	0 (0.0)	9
Pharyngeal	2019	5 (71.4)	0 (0.0)	1 (100.0)	6
Pharyngeal	2020	7 (58.3)	1 (50.0)	2 (66.7)	10
Rectal	2018	4 (28.6)	0 (0.0)	0 (0.0)	4
Rectal	2019	6 (35.3)	1 (100.0)	0 (0.0)	7
Rectal	2020	12 (54.5)	0 (0.0)	0 (0.0)	12

Note: MSM = Gay, bisexual, and other men who have sex with men; MSW = Men who have sex with women only. Ciprofloxacin resistance = MICs \geq 1.0 μ g/ml.